• News & Events
  • News
  • Atriva Therapeutics Reports Results of ATR-002 Phase I Clinical Trial

Host with the most: Targeting host cells instead of pathogens to fight infectious disease

In a recent news article published in Nature Medicine by Amanda B. Keener, the background of Atriva's antiviral MEK inhibitor technology was highlighted. Three of our founders were interviewed in this article and shared their views on past and future developments in influenza treatment:

Nature Medicine 23, 528–531 (2017) doi:10.1038/nm0517-528

Media Coverage

 

Events & Presentations

Please note that, due to the current coronavirus crisis, many conferences have been canceled or postponed.

Feel free to contact us any time.

Address

Atriva Therapeutics GmbH
Eisenbahnstr. 1, 72072 Tübingen

+49 (0)7071 8597673
info@atriva-therapeutics.com

LinkedIn
Twitter

In order to be able to design our website in the best possible way and to continuously improve it, we are using cookies. By continuing to use our website, you permit the use of cookies. More information can be found in our data protection rules.